China's NMPA approves Milestone's etripamil nasal spray for PSVT
The approval, Milestone's first outside the United States, triggers a $2.0 million milestone payment and hands commercialization in Greater China to Everest Medicines.
SEC filing
Latest
2 stories
Thursday, September 3
Wednesday, August 12
Milestone activates sites for Phase 3 AFib-RVR trial, reports $170.6M cash
Milestone said its ReVeRA-301 trial for etripamil in AFib-RVR is open with sites activated, while first patient enrollment remains targeted for the second half of 2026.
SEC filing